2010 Leadership in Pharmaceuticals and Biotechnology Forum
2010 Leadership in Pharmaceuticals and Biotechnology Forum
22 June 2010
New York, New York U.S.A.
As the pharmaceutical and biotech industries face pending healthcare and biologics legislation, the future of the industry remains in flux. Many companies have generics coming off patent necessitating discussion on new investments, pipeline issues and increased research & development.
The Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology event to bring together approximately 100 - 115 CEOs and complementary areas of executive leadership, from large and midsized pharmaceutical and biotech companies, founders/senior managing partners of investment firms that focus on pharmaceuticals, and biotechnology and select advisors.
Deal Making in the Pharmaceutical and Biotech Industries
Panel discussion topics:
- How will economic recovery play a role in pharmaceutical M&A? As the recession begins to subside, will we continue to see an uptick in deals?
- Predictions on where deals will be found going forward.
- What deal structure is going to work given the changing regulatory landscape?
Moderator:
Paunie Samreth, Reporter, mergermarket
Panelists:
Chris Garabedian, Vice President, Corporate Strategy, Celgene Corporation
Adam Golden, Partner and Co-Chair, Life Sciences Group, Kaye Scholer LLP
Reid J. Leonard, Ph.D., Executive Director, Licensing & External Research, Merck Research Laboratories
Elizabeth Stoner, M.D., M.S., Managing Director, MPM Capital
Mike Wise, Vice President and Partner, A.T. Kearney
|
